SummaryWHO has issued its first-ever guidance recommending GLP-1 drugs for long-term obesity management, marking a major shift from its earlier focus on lifestyle changes alone. Published in JAMA, the guideline cites strong evidence that GLP-1 therapies support meaningful weight loss and reduce health risks when combined with diet, exercise, and counseling.